Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

The IDentif.AI 2.0 Pandemic Readiness Platform: Rapid Prioritization of Optimized COVID-19 Combination Therapy Regimens

Agata Blasiak, Anh T.L. Truong, Alexandria Remus, Lissa Hooi, Shirley Gek Kheng Seah, Peter Wang, De Hoe Chye, Angeline Pei Chiew Lim, Kim Tien Ng, Swee Teng Teo, Yee-Joo Tan, David Michael Allen, Louis Yi Ann Chai, Wee Joo Chng, Raymond T.P. Lin, David C.B. Lye, John Eu-Li Wong, Gek-Yen Gladys Tan, Conrad En Zuo Chan, Edward Kai-Hua Chow, View ORCID ProfileDean Ho
doi: https://doi.org/10.1101/2021.06.23.21259321
Agata Blasiak
1The Institute for Digital Medicine (WisDM), Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117456
2The N.1 Institute for Health (N.1), National University of Singapore, Singapore 117456
3Deparment of Biomedical Engineering, NUS Engineering, National University of Singapore, Singapore 117583
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: agata.blasiak@nus.edu.sg cenzuo@dso.org.sg csikce@nus.edu.sg biedh@nus.edu.sg
Anh T.L. Truong
1The Institute for Digital Medicine (WisDM), Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117456
2The N.1 Institute for Health (N.1), National University of Singapore, Singapore 117456
3Deparment of Biomedical Engineering, NUS Engineering, National University of Singapore, Singapore 117583
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandria Remus
1The Institute for Digital Medicine (WisDM), Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117456
2The N.1 Institute for Health (N.1), National University of Singapore, Singapore 117456
3Deparment of Biomedical Engineering, NUS Engineering, National University of Singapore, Singapore 117583
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lissa Hooi
4Cancer Science Institute of Singapore, National University of Singapore, Singapore 117599
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shirley Gek Kheng Seah
5Defence Medical and Environmental Research Institute, DSO National Laboratories, Singapore, Singapore 117510
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Wang
1The Institute for Digital Medicine (WisDM), Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117456
2The N.1 Institute for Health (N.1), National University of Singapore, Singapore 117456
3Deparment of Biomedical Engineering, NUS Engineering, National University of Singapore, Singapore 117583
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
De Hoe Chye
5Defence Medical and Environmental Research Institute, DSO National Laboratories, Singapore, Singapore 117510
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angeline Pei Chiew Lim
5Defence Medical and Environmental Research Institute, DSO National Laboratories, Singapore, Singapore 117510
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kim Tien Ng
6Infectious Diseases Translational Research Program, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, 117545
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Swee Teng Teo
6Infectious Diseases Translational Research Program, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, 117545
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yee-Joo Tan
6Infectious Diseases Translational Research Program, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, 117545
7Institute of Molecular and Cell Biology (IMCB), A*STAR, Singapore, 138673
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Michael Allen
8Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228
9Division of Infectious Diseases, National University Hospital, Singapore 119074
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Louis Yi Ann Chai
8Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228
9Division of Infectious Diseases, National University Hospital, Singapore 119074
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wee Joo Chng
4Cancer Science Institute of Singapore, National University of Singapore, Singapore 117599
8Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228
10Department of Haematology-Oncology, National University Cancer Institute, Singapore, National University Hospital 119074
11NUS Centre for Cancer Research (N2CR), Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117599
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raymond T.P. Lin
12National Centre for Infectious Diseases (NCID), Jalan Tan Tock Seng, Singapore 308442
13Department of Laboratory Medicine, National University Hospital, Singapore 119074
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David C.B. Lye
8Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228
12National Centre for Infectious Diseases (NCID), Jalan Tan Tock Seng, Singapore 308442
14Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 308232
15Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore 308433
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Eu-Li Wong
8Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228
10Department of Haematology-Oncology, National University Cancer Institute, Singapore, National University Hospital 119074
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gek-Yen Gladys Tan
5Defence Medical and Environmental Research Institute, DSO National Laboratories, Singapore, Singapore 117510
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Conrad En Zuo Chan
5Defence Medical and Environmental Research Institute, DSO National Laboratories, Singapore, Singapore 117510
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: agata.blasiak@nus.edu.sg cenzuo@dso.org.sg csikce@nus.edu.sg biedh@nus.edu.sg
Edward Kai-Hua Chow
1The Institute for Digital Medicine (WisDM), Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117456
2The N.1 Institute for Health (N.1), National University of Singapore, Singapore 117456
3Deparment of Biomedical Engineering, NUS Engineering, National University of Singapore, Singapore 117583
4Cancer Science Institute of Singapore, National University of Singapore, Singapore 117599
11NUS Centre for Cancer Research (N2CR), Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117599
16Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: agata.blasiak@nus.edu.sg cenzuo@dso.org.sg csikce@nus.edu.sg biedh@nus.edu.sg
Dean Ho
1The Institute for Digital Medicine (WisDM), Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117456
2The N.1 Institute for Health (N.1), National University of Singapore, Singapore 117456
3Deparment of Biomedical Engineering, NUS Engineering, National University of Singapore, Singapore 117583
16Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dean Ho
  • For correspondence: agata.blasiak@nus.edu.sg cenzuo@dso.org.sg csikce@nus.edu.sg biedh@nus.edu.sg
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Objectives We aimed to harness IDentif.AI 2.0, a clinically actionable AI platform to rapidly pinpoint and prioritize optimal combination therapy regimens against COVID-19.

Methods A pool of starting candidate therapies was developed in collaboration with a community of infectious disease clinicians and included EIDD-1931 (metabolite of EIDD-2801), baricitinib, ebselen, selinexor, masitinib, nafamostat mesylate, telaprevir (VX-950), SN-38 (metabolite of irinotecan), imatinib mesylate, remdesivir, lopinavir, and ritonavir. Following the initial drug pool assessment, a focused, 6-drug pool was interrogated at 3 dosing levels per drug representing nearly 10,000 possible combination regimens. IDentif.AI 2.0 paired prospective, experimental validation of multi-drug efficacy on a SARS-CoV-2 live virus (propagated, original strain, B.1.351 and B.1.617.2 variants) and Vero E6 assay with a quadratic optimization workflow.

Results Within 3 weeks, IDentif.AI 2.0 realized a list of combination regimens, ranked by efficacy, for clinical go/no-go regimen recommendations. IDentif.AI 2.0 revealed EIDD-1931 to be a strong candidate upon which multiple drug combinations can be derived.

Conclusions IDentif.AI 2.0 rapidly revealed promising drug combinations for clinical translation. It pinpointed dose-dependent drug synergy behavior to play a role in trial design and realizing positive treatment outcomes. IDentif.AI 2.0 represents an actionable path towards rapidly optimizing combination therapy following pandemic emergence.

Figure
  • Download figure
  • Open in new tab

Highlights

  • - When novel pathogens emerge, the immediate strategy is to repurpose drugs.

  • - Good drugs delivered together in suboptimal combinations and doses can yield low or no efficacy, leading to misperception that the drugs are ineffective.

  • - IDentif.AI 2.0 does not use in silico modeling or pre-existing data.

  • - IDentif.AI 2.0 pairs optimization with prospectively acquired experimental data using a SARS-CoV-2/Vero E6 assay.

  • - IDentif.AI 2.0 pinpoints EIDD-1931 as a foundation for optimized anti-SARS-CoV-2 combination therapies.

Competing Interest Statement

A. B., E. K-.H. C., and D. H. are co-inventors or previously filed pending patents on artificial intelligence-based therapy development. E. K.-H. C., and D. H. are shareholders of KYAN Therapeutics, which has licensed intellectual property pertaining to AI-based oncology drug development. The findings from this study are being made available for public benefit, and no intellectual property rights arising from the work reported here are being pursued.

Funding Statement

D. H. gratefully acknowledges support from the Office of the President, Office of the Senior Deputy President and Provost, and Office of the Deputy President for Research and Technology at the National University of Singapore. D. H also gratefully acknowledges funding from the Institute for Digital Medicine (WisDM) Translational Research Programme [grant number R-719-000-037-733] at the Yong Loo Lin School of Medicine, National University of Singapore, Ministry of Education Tier 1 FRC Grant [grant number R-397-000-333-114], Micron Foundation, and Sun Life Singapore. D. H. and E. K.-H. C. gratefully acknowledge the National Research Foundation Singapore under its AI Singapore Programme [Award Number: AISG-GC-2019-002], and Singapore Ministry of Health's National Medical Research Council under its Open Fund- Large Collaborative Grant (OF-LCG) [grant number MOH-OFLCG18May-0028]. E. K.-H. C. is supported by the National Research Foundation Singapore and the Singapore Ministry of Education under its Research Centres of Excellence Initiative (Cancer Science Institute of Singapore RCE Main Grant), Ministry of Education Academic Research Fund (MOE AcRF Tier 2 [grant number MOE2019-T2-1-115]), Singapore Ministry of Health's National Medical Research Council under its Open Fund- Large Collaborative Grant (OF-LCG) [grant numbers MOH-OFLCG18May-0023 and MOH-OFLCG18May-0028] and National Research Foundation Competitive Proton Research Programme [grant number NRF-CRP-2017-05]. S. G. K. S., D. H. C., A.P.C.L., G.-Y.G.T. and C. E. Z. C. gratefully acknowledge funding support from Future Systems and Technology Directorate, Singapore Ministry of Defence. Any opinions, findings and conclusions or recommendations expressed in this material are those of the author(s) and do not reflect the views of National Research Foundation, Singapore.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This work was conducted under study number 2012/00917 approved by the Domain Specific Review Board, as well as approved OSHE/iORC protocol 2020-00494.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* Co-first authors

  • This preprint draft includes the following revisions: - We have added a new figure showing the experimental validation of the regimens identified in Preprint Version 1 in the Delta variant of SARS-CoV-2 (Note: this work is based on experimentally-driven regimen optimization, and is not a computational modeling study). We have provided additional materials/methods details in the supplementary materials as well. - We have added additional authors who contributed to the studies pertaining to the new data. - We have made minor grammatical edits.

Data Availability

Data requests can be addressed to the corresponding authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted July 29, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
The IDentif.AI 2.0 Pandemic Readiness Platform: Rapid Prioritization of Optimized COVID-19 Combination Therapy Regimens
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The IDentif.AI 2.0 Pandemic Readiness Platform: Rapid Prioritization of Optimized COVID-19 Combination Therapy Regimens
Agata Blasiak, Anh T.L. Truong, Alexandria Remus, Lissa Hooi, Shirley Gek Kheng Seah, Peter Wang, De Hoe Chye, Angeline Pei Chiew Lim, Kim Tien Ng, Swee Teng Teo, Yee-Joo Tan, David Michael Allen, Louis Yi Ann Chai, Wee Joo Chng, Raymond T.P. Lin, David C.B. Lye, John Eu-Li Wong, Gek-Yen Gladys Tan, Conrad En Zuo Chan, Edward Kai-Hua Chow, Dean Ho
medRxiv 2021.06.23.21259321; doi: https://doi.org/10.1101/2021.06.23.21259321
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
The IDentif.AI 2.0 Pandemic Readiness Platform: Rapid Prioritization of Optimized COVID-19 Combination Therapy Regimens
Agata Blasiak, Anh T.L. Truong, Alexandria Remus, Lissa Hooi, Shirley Gek Kheng Seah, Peter Wang, De Hoe Chye, Angeline Pei Chiew Lim, Kim Tien Ng, Swee Teng Teo, Yee-Joo Tan, David Michael Allen, Louis Yi Ann Chai, Wee Joo Chng, Raymond T.P. Lin, David C.B. Lye, John Eu-Li Wong, Gek-Yen Gladys Tan, Conrad En Zuo Chan, Edward Kai-Hua Chow, Dean Ho
medRxiv 2021.06.23.21259321; doi: https://doi.org/10.1101/2021.06.23.21259321

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1097)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (502)
  • Epidemiology (9773)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2313)
  • Geriatric Medicine (223)
  • Health Economics (462)
  • Health Informatics (1562)
  • Health Policy (736)
  • Health Systems and Quality Improvement (604)
  • Hematology (238)
  • HIV/AIDS (504)
  • Infectious Diseases (except HIV/AIDS) (11650)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (238)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2144)
  • Nursing (134)
  • Nutrition (337)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1180)
  • Ophthalmology (364)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (147)
  • Palliative Medicine (50)
  • Pathology (311)
  • Pediatrics (695)
  • Pharmacology and Therapeutics (300)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2182)
  • Public and Global Health (4663)
  • Radiology and Imaging (778)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (624)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (210)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)